Zobrazeno 1 - 10
of 52
pro vyhledávání: '"LAI-SAN THAM"'
Autor:
Atsunori Kaibara, Ao Peng, Rujia Xie, Yunn‐Fang Ho, Chun‐Jung Lin, Lai‐San Tham, Surulivelrajan Mallayasamy, Korbtham Sathirakul, Yoke‐Lin Lo, Manh Hung Tran, Van Toi Pham, Akhmad Kharis Nugroho, Khin Myo Oo, Bimal Kunwar, Uthpali Mannapperuma, Kimheang Ya, Muhammad Usman, Long Chiau Ming, Kyungsoo Park
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 4, Pp 403-408 (2022)
Externí odkaz:
https://doaj.org/article/49ccadfe50ad45c2b13c7a3633b6cc62
Autor:
Bridget L. Morse, Jeffrey J. Alberts, Maria M. Posada, Jessica Rehmel, Anil Kolur, Lai San Tham, Corina Loghin, Kathleen M. Hillgren, Stephen D. Hall, Gemma L. Dickinson
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 9, Pp 664-675 (2019)
The drug–drug interaction profile of atorvastatin confirms that disposition is determined by cytochrome P450 (CYP) 3A4 and organic anion transporting polypeptides (OATPs). Drugs that affect gastric emptying, including dulaglutide, also affect atorv
Externí odkaz:
https://doaj.org/article/2a273e5063874e24aca5d62fecd6337f
Autor:
CHARLES BENSON, LAI-SAN THAM, YU DU, SIREL GURBUZ, DEBORAH A. ROBINS, KIEREN J. MATHER, CHENG CAI TANG, MELISSA K. THOMAS
Publikováno v:
Diabetes. 71
LY is an acylated peptide analog of oxyntomodulin, a dual glucagon and GLP-1 receptor agonist. We conducted 2 randomized, double-blind, phase 1 multiple ascending subcutaneous dosing studies in healthy subjects (S1, NCT03325387) and in T2D patients (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da6546f5511140d04601d7757016dbef
https://doi.org/10.2337/db22-333-or
https://doi.org/10.2337/db22-333-or
Autor:
Kashif M. Munir, Kathleen Dungan, Manige Konig, Lai San Tham, Anita Y. M. Kwan, Cheng Cai Tang, Kevin M. Pantalone
Publikováno v:
Diabetes, obesitymetabolism. 24(2)
Aims To evaluate HbA1c and body weight changes when semaglutide 0.5 mg or 1.0 mg once weekly (QW) is switched to dulaglutide 3.0 mg or 4.5 mg QW via exposure-response modelling. Materials and methods HbA1c and body weight time-course models were deve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::533b24383d09c527afa144c616d53dd0
https://pubmed.ncbi.nlm.nih.gov/34697882
https://pubmed.ncbi.nlm.nih.gov/34697882
Autor:
Yifei Zhang, Weiqing Wang, Weiwei Zhou, Junyu Xu, Yimin Cui, Yiming Li, Corina Loghin, Lai San Tham, Xuewei Cui, Xia Zhao
Publikováno v:
Advances in therapy. 39(1)
This study evaluated the pharmacokinetics, pharmacodynamics, and safety of a single dulaglutide dose in Chinese healthy subjects and of multiple dulaglutide doses in Chinese patients with type 2 diabetes mellitus (T2DM). This two-part, double-blind,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f03d5bb933db6451313668436ac5e294
https://pubmed.ncbi.nlm.nih.gov/34787823
https://pubmed.ncbi.nlm.nih.gov/34787823
Autor:
Manige Konig, Kathleen Dungan, Kevin M. Pantalone, Kashif M. Munir, Cheng Cai Tang, Anita Kwan, Lai-San Tham
Publikováno v:
Diabetes. 70
Dulaglutide 3.0 and 4.5 mg subcutaneous (SC) once weekly (QW) doses are approved for glycemic control in patients with type 2 diabetes (T2D). Using pharmacokinetic/pharmacodynamic models built from and validated with published data from SUSTAIN 1 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3ffa2aa05afa08492a68fea50110a1e
https://doi.org/10.2337/db21-643-p
https://doi.org/10.2337/db21-643-p
Publikováno v:
Diabetes. 70
Dulaglutide (DU) 3 mg and 4.5 mg once weekly (QW) doses were recently approved for additional glycemic control in adult patients with type 2 diabetes. If needed, a dose-escalation scheme from 1.5 mg to 3 mg and then 4.5 mg can be applied after at lea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93b7957d961ad9b0b599e4f628705739
https://doi.org/10.2337/db21-642-p
https://doi.org/10.2337/db21-642-p
Publikováno v:
Diabetes. 70
LY3305677 (LY) is an acylated single chain peptide analog of mammalian oxyntomodulin designed for once weekly dosing. It has dual pharmacology of GLP-1 and glucagon and has therapeutic potential for T2D, obesity and NASH. This randomized, double blin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71117499ba755b35c45ef5ab307889bb
https://doi.org/10.2337/db21-106-or
https://doi.org/10.2337/db21-106-or
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kathleen M. Hillgren, Bridget L. Morse, Lai San Tham, Maria M. Posada, Gemma L. Dickinson, Stephen D. Hall, Corina Loghin, Jessica Rehmel, Anil Kolur, Jeffrey J. Alberts
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 9, Pp 664-675 (2019)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
The drug–drug interaction profile of atorvastatin confirms that disposition is determined by cytochrome P450 (CYP) 3A4 and organic anion transporting polypeptides (OATPs). Drugs that affect gastric emptying, including dulaglutide, also affect atorv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a2440c74a085f6fbbce159b840e0088
https://doi.org/10.1002/psp4.12447
https://doi.org/10.1002/psp4.12447